Transaction DateRecipientSharesTypePriceValue
19th October 2020Fred E Cohen10,000Exercise of derivative$7.60$76,000.00
15th October 2020Jose E Rivera10,000Exercise of derivative$6.83$68,300.00
15th October 2020Jose E Rivera5,459Open or private sale$24.19$132,053.21
15th October 2020Jose E Rivera156Open or private sale$24.55$3,829.80
7th October 2020John M. Leonard5,000Exercise of derivative$6.83$34,150.00
7th October 2020John M. Leonard5,000Open or private sale$21.83$109,150.00
21st September 2020Fred E Cohen9,745Exercise of derivative$4.95$48,237.75
21st September 2020Fred E Cohen6,679Exercise of derivative$5.49$36,667.71
15th September 2020Jose E Rivera5,615Open or private sale$21.04$118,139.60
15th September 2020Jose E Rivera10,000Exercise of derivative$6.83$68,300.00
Intellia Therapeutics
Intellia Therapeutics logo

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing.

Ticker: NTLA
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1652130
Employees: 270
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $81 M (41%)
Marketable Securities, Current: $169 M (-23%)
Assets, Current: $270 M (-6%)
Property, Plant and Equipment, Net: $17 M (-4%)
Other Assets, Noncurrent: $3 M (-3%)
Assets: $315 M (-5%)
Accounts Payable, Current: $4 M (-1%)
Accrued Liabilities, Current: $13 M (0%)
Liabilities, Current: $35 M (0%)
Common Stock, Value, Issued: $5 Th (0%)
Common Stock, Shares, Issued: $51 M (0%)
Additional Paid in Capital, Common Stock: $580 M (1%)
Retained Earnings (Accumulated Deficit): $333 M (10%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $373 Th (42%)
Stockholders' Equity (Parent): $248 M (0%)
Liabilities and Equity: $315 M (-5%)
Revenue: $13 M (23%)
Research and Development: $35 M (46%)
General and Administrative Expenses: $11 M (7%)
Operating Income/Loss: $33 M (38%)